Prognostic factors | All patients | E-cadherin | P | Nuclear β-catenin | P | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Absence vs. presence | Absence vs. presence | |||||||||||
N | % | N | % | N | % | N | % | N | % | |||
98 | 100 | 46 | 47% | 52 | 53% | 74 | 76% | 24 | 24 | |||
Sex | ||||||||||||
Male | 72 | 73% | 33 | 46% | 39 | 54% | P=0.4 | 56 | 78% | 16 | 22% | P=0.4 |
Female | 26 | 27% | 13 | 50% | 13 | 50% | 18 | 69% | 8 | 31% | ||
Age | P=0.9 | |||||||||||
</= 50 | 48 | 49% | 9 | 64% | 36% | 5 | P=0.6 | 10 | 71% | 4 | 29% | |
>50 | 50 | 51% | 37 | 44% | 47 | 56% | 64 | 76% | 20 | 24% | ||
Distance to anal margin | P=0.7 | |||||||||||
</= 5 cm | 84 | 86% | 22 | 46% | 26 | 54% | P=0.8 | 38 | 79% | 10 | 21% | |
>5 cm | 14 | 14% | 24 | 48% | 26 | 52% | 36 | 72% | 14 | 28% | ||
T stage | P=0.4 | |||||||||||
T2-3 | 82 | 83% | 38 | 47% | 42 | 53% | P=0.8 | 59 | 74% | 21 | 26% | |
T4 | 17 | 17% | 8 | 44% | 10 | 56% | 15 | 83% | 3 | 17% | ||
N stage | P=0.2 | |||||||||||
N- | 43 | 44% | 19 | 43% | 25 | 57% | P=0.5 | 19 | 43% | 25 | 57% | |
N+ | 55 | 56% | 27 | 50% | 37 | 50% | 22 | 41% | 32 | 59% | ||
TGR* | P=0.6 | |||||||||||
TGR 1-2 | 44 | 45% | 18 | 41% | 26 | 59% | P=0.2 | 32 | 73% | 12 | 27% | |
TGR 3-5 | 54 | 55% | 28 | 52% | 26 | 48% | 42 | 78% | 12 | 22% | ||
pN †† | P=0.8 | P=0.9 | ||||||||||
pN- | 70 | 71% | 20 | 74% | 7 | 26% | 30 | 44% | 41 | 56% | ||
pN+ | 28 | 29% | 54 | 76% | 17 | 24% | 11 | 41% | 16 | 59% |